MilliporeSigma
  • A survival case of visceral disseminated varicella zoster virus infection in a patient with systemic lupus erythematosus.

A survival case of visceral disseminated varicella zoster virus infection in a patient with systemic lupus erythematosus.

BMC nephrology (2023-06-09)
Yuri Ishino, Hirotaka Fukasawa, Shuhei Kitamoto, Daisuke Nakagami, Mai Kaneko, Hideo Yasuda, Ryuichi Furuya
ABSTRACT

Visceral disseminated varicella zoster virus (VZV) infection is a rare but life-threatening complication in immunosuppressed patients. Herein, we report a survival case of visceral disseminated VZV infection in a patient with systemic lupus erythematosus (SLE). A 37-year-old woman was diagnosed as SLE and initial induction therapy was started. Two months after starting the immunosuppressive therapy consisting of 40 mg of prednisolone (PSL) and 1500 mg of mycophenolate mofetil (MMF) daily, she suddenly developed strong abdominal pain, which was required opioid analgesics, followed by systemic skin blisters, which were diagnosed as varicella. Laboratory findings showed rapid exacerbation of severe liver failure, coagulation abnormalities and increased numbers of blood VZV deoxyribonucleic acid (DNA). Therefore, she was diagnosed as visceral disseminated VZV infection. Multidisciplinary treatment with acyclovir, immunoglobulin and antibiotics was started, the dose of PSL was reduced, and MMF was withdrawn. By their treatment, her symptoms were resolved and she finally discharged. Our case highlights the importance of a clinical suspicion of visceral disseminated VZV infections, and the necessity of immediate administration of acyclovir and reduced doses of immunosuppressant to save patients with SLE.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Varicella-Zoster Virus Antibody, Glycoprotein I, Chemicon®, from mouse